Tickabril Tablets 60mg (Ticagrelor)

Adult dose

Do not use this medicine concomitantly with other ADP receptor inhibitors (ticlopidine, clopidogrel, prasugrel). Acute coronary syndrome: Administer an initial dose of 180mg, followed by 90mg twice daily. Treatment for 12 months is recommended unless discontinuation is clinically necessary. Patients taking this medicine should also receive a maintenance dose of aspirin (75 - 150mg), unless specifically contraindicated. Patients with a history of myocardial infarction (occurring at least 1 year previously) who are at high risk of thrombotic cardiovascular events: Administer 60mg twice daily. Patients taking this medicine should also receive a maintenance dose of aspirin (75 - 150mg), unless specifically contraindicated. Patients who took 90mg of this medicine or another ADP receptor inhibitor (ticlopidine, clopidogrel, prasugrel) during the first year after myocardial infarction may continue treatment with 60mg of this medicine. Treatment with this medicine may also be initiated in patients within 2 years after myocardial infarction or within 1 year after discontinuing a previous ADP receptor inhibitor (ticlopidine, clopidogrel, prasugrel). Patients with type 2 diabetes who have undergone percutaneous coronary intervention (PCI) for coronary artery disease: Administer 60mg twice daily. Patients taking this medicine should also receive a maintenance dose of aspirin (75 - 150mg), unless specifically contraindicated. For patients with acute coronary syndrome, refer to the relevant dosage and administration instructions. Patients with acute ischemic stroke or high-risk transient ischemic attack: Administer an initial dose of 180mg, followed by 90mg twice daily for 30 days. Patients taking this medicine should also receive a maintenance dose of aspirin (75 - 100mg), unless specifically contraindicated. An initial loading dose of aspirin (300-325mg) is recommended in patients with acute ischemic stroke or high-risk transient ischemic attack. This medicine is administered orally and may be taken with or without food. For patients who have difficulty swallowing tablets, crush this medicine into a fine powder, disperse it in half a glass of water, and drink it. Rinse the glass with another half glass of water and drink it. This mixture may also be administered through a nasogastric tube (CH8 or larger); it is important to flush the tube with water after administration. When switching from another antiplatelet agent to this medicine, start this medicine 24 hours after the last dose of the previous medicine. If a dose is missed, take only 1 tablet (the next scheduled dose) at the next scheduled dosing time. No dose adjustment is necessary in patients with renal impairment. No dose adjustment is necessary in patients with mild hepatic impairment. This medicine has not been studied in patients with severe hepatic impairment, and there is limited experience with its use in patients with moderate hepatic impairment.

Child dose

The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age (see Other section).

This medication inhibits the function of platelets to prevent blood from clotting and forming thrombi. Therefore, it should not be administered to patients at high risk of bleeding, particularly those with active pathological bleeding or a history of intracranial hemorrhage. If a surgery is planned, this medication must be discontinued at least 5 days before the procedure, and any signs of bleeding should be reported immediately to medical staff. This medication may exacerbate side effects due to interactions with certain liver diseases or drugs, so patients with severely impaired liver function or those taking strong CYP3A4 inhibitors should not use it. Caution should be exercised when used with other drugs that may increase the risk of bleeding, especially nonsteroidal anti-inflammatory drugs, anticoagulants, and high-dose aspirin. Patients experiencing bradycardia (slow heart rate) or shortness of breath should consult a physician before using this medication. Women who are pregnant or breastfeeding may risk harm to the fetus or newborn while taking this medication, so they should consult healthcare providers if they are planning to get pregnant or are pregnant. Additionally, this medication is not recommended for children under 18, as safety and efficacy have not been established. In cases of overdose, the risk of bleeding may increase, so immediate medical attention is necessary. During the course of taking this medication, patients may experience symptoms such as dizziness or confusion, so caution is advised when driving or operating machinery. Finally, this medication should be stored in its original container and kept out of reach of children.

Hemorrhage, intracranial hemorrhage, ocular hemorrhage, ear hemorrhage, hypotension, respiratory distress, respiratory tract hemorrhage, gastrointestinal hemorrhage, diarrhea, nausea, indigestion, constipation, retroperitoneal hemorrhage, skin hemorrhage, rash, itching, muscle hemorrhage, urinary tract hemorrhage, reproductive tract hemorrhage, post-procedural hemorrhage, traumatic hemorrhage, thrombotic thrombocytopenic purpura, bradyarrhythmia, atrioventricular block, angioedema, confusion, dizziness, syncope, headache, vertigo, ear hemorrhage, elevated serum creatinine, chest pain, pulmonary hemorrhage, pharyngitis, upper respiratory infection, asthma, pleural effusion, bronchitis, pneumothorax, pneumonia, pulmonary edema, weakness, anaphylactic shock, epistaxis, hemoptysis, hematoma, cerebral hemorrhage, spinal canal stenosis, dementia, migraine, paralysis, gait abnormalities, rectal hemorrhage, anal hemorrhage, appendicitis, tendon disease, bursitis, rhabdomyolysis, diabetes mellitus, hyperkalemia, hyperglycemia, thirst, hepatitis, snoring, aneurysm, heart failure, palpitations, ventricular tachycardia, arrhythmia, ventricular fibrillation, cardiac arrest, ventricular fibrillation, urinary tract infection, kidney stones, cerebral ischemia, venous stenosis, cerebral infarction, arterial stenosis, angina, coronary thrombosis, myocardial ischemia, fungal infection, anemia, vestibular disorder, malignant neoplasm of the male reproductive system, chemical poisoning, post-procedural hematoma, laceration, road traffic accident, trauma, nausea, vomiting, acute renal failure, exacerbation of hypertension, atrial fibrillation, polyuria, dysuria, conjunctival injection, ocular pain, visual disturbances, arterial stenosis, angina, myocardial infarction, insomnia, anxiety, memory disturbances, erectile dysfunction, restlessness, orthostatic hypotension, palpitations, bradycardia, atrial fibrillation, tinnitus, ear pain, lymphadenopathy, eosinophilia, sexual dysfunction, benign prostatic hyperplasia, ovarian cyst, amenorrhea, vaginitis, loss of taste, altered sense of smell, elevated TSH, hypothyroidism, injection site reaction, injection site pain, urticaria, increased sweating

This medication should be stored in a tightly closed container to prevent air or moisture from entering, and it is best kept at room temperature between 1 and 30 degrees Celsius. Proper storage will help maintain the effectiveness of the medication for longer.

Appearance

Pink, oval, film-coated tablet with a biconvex shape.

Package unit

10 tablets/PTP [60 tablets (10 tablets/PTP x 6)]